The Management Board of Captor Therapeutics S.A. announces the conclusion of a cooperation agreement with the renowned MD Anderson Cancer Center (MDACC) at The University of Texas. The purpose of the agreement is to support the execution of an Investigator-Initiated Trial (IIT), which will be conducted by MD Anderson. The trial concerns Captor’s lead drug candidate – an MCL-1 protein degrader, intended for the treatment of hematological malignancies.
The clinical trial builds upon groundbreaking preclinical research conducted at MD Anderson by a team led by Professors Michael Andreeff and Bing Carter, in close collaboration with Captor. These studies demonstrated that the clinical candidate, CT-03p, effectively reduces MCL-1 protein levels, induces the death of leukemic cells, and exhibits a synergistic effect with the BCL-2 inhibitor in treatment-resistant cells. Dr. Abhishek Maiti, Assistant Professor in the Department of Leukemia at MD Anderson, will serve as the Principal Investigator for the project. Updated preclinical data, which forms the basis for initiating the IIT, will be presented in December 2025 at the American Society of Hematology Annual Meeting (ASH 2025).
Collaboration with MD Anderson, a global leader in oncology, constitutes a key step in the clinical development of CT-03p and affirms the global recognition of Captor Therapeutics' innovative technology.
